A Study of Pharmacological Management of Hospitalized Patients of Malaria at A Tertiary Care Teaching Hospital
DOI:
https://doi.org/10.70284/njirm.v9i2.2312Keywords:
P.falciparum, P.vivax, Chloroquine, ACTAbstract
Aims & objectives: The present study was aimed to study usage pattern of drugs used in management of hospitalized patients of malaria and to monitor any adverse drug reactions occurring during the course of the given treatment in malaria patients. Methods: This prospective, observational, single centre study was carried out in 2 units of each Medicine and Paediatric Department of Civil Hospital, Ahmadabad. All the relevant details of hospitalized patients of malaria willing to participate in the study were recorded in a pre-decided case record form. Relevant statistical tests were employed wherever necessary. Results: A total of 87 hospitalized patients of malaria were studied during the period of one year. In our study, we found that type of malaria was P.vivax malaria in 49 (56.32 %) patients, P.falciparummalaria in 34 (39.08 %) patients and mixed infection malaria in 4 (4.59 %). Most commonly prescribed anti malarial in these patients was chloroquine (n=63, 72.4%). For prophylaxis, out of 87 patients, 72 (82.75%) patients were prescribed primaquine. Out of 87 patients, 21 ADRs were observed among 21 patients. The commonest ADRs were rash (n=9) and pruritus (n=6). Commonest suspected drug was chloroquine (n=12) followed by primaquine (n=6). Conclusion: Despite some limitations this study has made several important conclusions and useful suggestions can be made for future use of anti malarials. Prevention and treatment of malaria especially in Indian setup (limited resources, lack and cost of laboratory investigations, non availability of newer drugs) should be outlined in a rational manner.
References
2. Sharma VP. Current scenario of malaria in India. Parassitologia. 2000;41:349–353. [PubMed]
3. Valecha N, Joshi H, Mallick PK, et al. Low efficacy of chloroquine: time to switch over to artemisinin based combination therapy for falciparum malaria in India. Acta Trop. 2009;111:21–28. [PubMed]
4. World malaria report 2013. Geneva: World Health Organization,2013., http://www.who.int/malaria/areas/treatment/overview/en/{last accessed on 2013 Feb 12}
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. ClinPharmacolTher. 1981;30:239–45. [PubMed]
6. Faheem Mubeen, Hardeep, Pandey D, Mujawar J; Drug utilization pattern of antimalarial drugs at a tertiary care hospital; A retrospective study; Int J Med Pharm Sci, Jan 2013/ Vol 03 (05)
7. Kochara DK, Sirohia P, Budaniab MP, Lakhotiab JP; Dynamics of malaria in Bikaner, Rajasthan, India (1975–2006); J Vector Borne Dis 44, December 2007, pp. 281–284
8. Kumar A, Valecha N, Jain T, Dash AP, Burden of Malaria in India: Retrospective and Prospective View; Am. J. Trop. Med. Hyg., 77(Suppl 6), 2007, pp. 69–78
9. Dash AP, Valecha N, Anvikar AR and Kumar A; Malaria in India: Challenges and opportunities; J. Biosci. 33(4), November 2008, 583–592
10. Harrison NE, Tolulope F, Chimere OA; Utilization of the current national antimalarial treatment guidelines among doctors in army hospitals in Lagos, Nigeria; Open journal of preventive medicine 2012, Vol 2;3;p390
11. Karunajeewa HA, Ivo M, Senn M, Enmoore L, Irwin L, Gomorrai PS et al.; A Trial of Combination Antimalarial Therapies in Children from Papua New Guinea; N Engl J Med 2008;359:2545-57
12. Ahmed ME, Yousif; Impact of the national protocol for malaria treatment on prescribing patterns in Gezira state, Sudan; East Mediterr Health J. 2004 Jul-Sep;10(4-5):566-72.
